A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma

IntroductionHigh-dose interleukin-2 (HD IL-2) and pembrolizumab are each approved as single agents by the U.S. F.D.A. for the treatment of metastatic melanoma. There is limited data using the agents concurrently. The objectives of this study were to characterize the safety profile of IL-2 in combina...

Full description

Bibliographic Details
Main Authors: Ann W. Silk, Brendan Curti, Jennifer Bryan, Tracie Saunders, Weichung Shih, Michael P. Kane, Phoebe Hannon, Christopher Fountain, Jessica Felcher, Andrew Zloza, Howard L. Kaufman, Janice M. Mehnert, David F. McDermott
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
melanoma
interleukin-2
cytokine
pembrolizumab
combination immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1108341/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1108341/full

Similar Items